KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Assets (2016 - 2025)

Pacific Biosciences Of California has reported Current Assets over the past 16 years, most recently at $375.1 million for Q4 2025.

  • Quarterly results put Current Assets at $375.1 million for Q4 2025, down 24.34% from a year ago — trailing twelve months through Dec 2025 was $375.1 million (down 24.34% YoY), and the annual figure for FY2025 was $375.1 million, down 24.34%.
  • Current Assets for Q4 2025 was $375.1 million at Pacific Biosciences Of California, down from $394.2 million in the prior quarter.
  • Over the last five years, Current Assets for PACB hit a ceiling of $1.2 billion in Q1 2021 and a floor of $375.1 million in Q4 2025.
  • Median Current Assets over the past 5 years was $852.1 million (2022), compared with a mean of $779.2 million.
  • Biggest five-year swings in Current Assets: skyrocketed 687.83% in 2021 and later tumbled 34.28% in 2025.
  • Pacific Biosciences Of California's Current Assets stood at $1.1 billion in 2021, then decreased by 22.62% to $852.1 million in 2022, then dropped by 12.91% to $742.0 million in 2023, then plummeted by 33.2% to $495.7 million in 2024, then dropped by 24.34% to $375.1 million in 2025.
  • The last three reported values for Current Assets were $375.1 million (Q4 2025), $394.2 million (Q3 2025), and $413.4 million (Q2 2025) per Business Quant data.